产品介绍 评论(0)
物种
Human分子别名
K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, GTPase KRas, KRAS2, RASK2Accession
P01116-2表达序列
Thr2-Cys185(Q61H) with His Tag at the C-Terminus
表达宿主
E.coli分子量
15-25kDa (Reducing)
纯度
>90% by SDS-PAGE活性
The specific activity of KRAS(Q61H) His Tag Protein, Human was determined to be > 290 pmol/min/mg in a GTPase-Glo assay using GTP solution substrate.标记
Unconjugated标签
His Tag性状
Liquid缓冲体系
50mM Tris, 200mM NaCl, 20% Glycerol, 1mM DTT, PH7.5
储存条件
Stable for 12 months upon stored at -80℃ from the date of receipt. And avoid repeated freeze-thaws cycles.
文献引用
1. Gremer L, Merbitz-Zahradnik T, Dvorsky R, Cirstea IC, Kratz CP, Zenker M, Wittinghofer A, Ahmadian MR. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat. 2011 Jan;32(1):33-43.
2. Serra RW, Fang M, Park SM, Hutchinson L, Green MR. A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife. 2014 Mar 12;3:e02313.
3. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl. 2012 Jun 18;51(25):6140-3.
KRAS is a small GTPase protein located at the inner cell membrane, functioning as a molecular switch that regulates cell proliferation and survival signals. The Q61H mutation resides in the Switch II region, impairing GTPase activity and locking the protein in a constitutively GTP-bound "active" state, leading to aberrant activation of MAPK/PI3K pathways. This mutation is commonly found in pancreatic, colorectal, and non-small cell lung cancers. Compared to KRAS G12 mutations, Q61H exhibits resistance to SHP2 inhibitors and is associated with worse prognosis. Clinical detection of this mutation provides crucial guidance for targeted therapy selection and prognostic evaluation.
电泳
1μg (R: reducing condition, N:non-reducing condition).







评论(0)